NO20002165L - Farmasøytiske blandinger inneholdende cyklodekstriner og taksoider - Google Patents

Farmasøytiske blandinger inneholdende cyklodekstriner og taksoider

Info

Publication number
NO20002165L
NO20002165L NO20002165A NO20002165A NO20002165L NO 20002165 L NO20002165 L NO 20002165L NO 20002165 A NO20002165 A NO 20002165A NO 20002165 A NO20002165 A NO 20002165A NO 20002165 L NO20002165 L NO 20002165L
Authority
NO
Norway
Prior art keywords
taxoids
pharmaceutical compositions
compositions containing
containing cyclodextrins
cyclodextrins
Prior art date
Application number
NO20002165A
Other languages
English (en)
Other versions
NO329382B1 (no
NO20002165D0 (no
Inventor
Joseph M Geczy
Original Assignee
Thissen Lab Sa
Cyclolab Company Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thissen Lab Sa, Cyclolab Company Ltd filed Critical Thissen Lab Sa
Publication of NO20002165D0 publication Critical patent/NO20002165D0/no
Publication of NO20002165L publication Critical patent/NO20002165L/no
Publication of NO329382B1 publication Critical patent/NO329382B1/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20002165A 1997-11-10 2000-04-27 Fremgangsmate for fremstilling av umiddelbart loselige, faste produkter, selve produktet samt anvendelse derav og fremgangsmate for forebyggelse av selvaggregering og prematur utfelling av et taksoid NO329382B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU9701945A HUP9701945A3 (en) 1997-11-10 1997-11-10 Pharmaceutical composition for injection containing cyclodextrin and taxoids
PCT/HU1998/000097 WO1999024073A1 (en) 1997-11-10 1998-11-09 Pharmaceutical compositions containing cyclodextrins and taxoids

Publications (3)

Publication Number Publication Date
NO20002165D0 NO20002165D0 (no) 2000-04-27
NO20002165L true NO20002165L (no) 2000-07-07
NO329382B1 NO329382B1 (no) 2010-10-04

Family

ID=89995733

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20002165A NO329382B1 (no) 1997-11-10 2000-04-27 Fremgangsmate for fremstilling av umiddelbart loselige, faste produkter, selve produktet samt anvendelse derav og fremgangsmate for forebyggelse av selvaggregering og prematur utfelling av et taksoid

Country Status (19)

Country Link
US (1) US7671042B2 (no)
EP (1) EP1059942B1 (no)
JP (1) JP3656550B2 (no)
KR (1) KR100607391B1 (no)
CN (1) CN1222321C (no)
AR (1) AR015482A1 (no)
AT (1) ATE387916T1 (no)
AU (1) AU742036B2 (no)
BR (1) BR9814015A (no)
CA (1) CA2309326C (no)
DE (1) DE69839224T2 (no)
EA (1) EA002776B1 (no)
HU (1) HUP9701945A3 (no)
IL (1) IL135990A0 (no)
NO (1) NO329382B1 (no)
NZ (1) NZ504098A (no)
PL (1) PL199652B1 (no)
WO (1) WO1999024073A1 (no)
ZA (1) ZA989779B (no)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020300A1 (es) 2000-08-22 2002-05-10 Pharmacia Corp Composicion de solucion de un farmaco antibiotico a base de oxazolidinona con mejoramiento de la carga de farmaco
WO2003015828A1 (en) * 2001-08-20 2003-02-27 Boehringer Ingelheim Pharmaceuticals, Inc. Parenteral formulations of 1-(5-tert-butyl-2-p-tolyl-2h-pryrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea and a cyclodextrin
CN100384865C (zh) * 2001-11-02 2008-04-30 嵌入治疗公司 用于rna干扰的治疗用途的方法及组合物
CN100518831C (zh) * 2002-08-15 2009-07-29 刘云清 固体纳米药物及其制备方法
AR054215A1 (es) 2006-01-20 2007-06-13 Eriochem Sa Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit
CN101020059B (zh) * 2006-02-15 2011-01-05 中国科学院上海药物研究所 一种含多烯紫杉醇类物质的药物组合物及其制备方法
KR100917809B1 (ko) 2006-05-22 2009-09-18 에스케이케미칼주식회사 우수한 저장안정성을 갖는 도세탁셀 함유 주사제 조성물
WO2007142440A1 (en) * 2006-06-02 2007-12-13 Sk Chemicals Co., Ltd. Stable pharmaceutical composition containing paclitaxel and a method of manufacturing the same
KR100917810B1 (ko) * 2006-06-02 2009-09-18 에스케이케미칼주식회사 저장안정성이 우수한 파클리탁셀 함유 주사제 조성물
CN100411688C (zh) * 2006-09-12 2008-08-20 南京师范大学 含有环糊精/多烯紫杉醇包合物的药物组合物及其制备方法
CN100486645C (zh) 2006-09-12 2009-05-13 南京师范大学 含有环糊精紫杉醇包合物的药物组合物及其制备方法
US20090022727A1 (en) 2007-01-26 2009-01-22 Alza Corp. Injectable, nonaqueous suspension with high concentration of therapeutic agent
CN102014918A (zh) * 2007-04-20 2011-04-13 太阳医药工业有限公司 由微量沉淀产生的药学组合物
JP2010530872A (ja) * 2007-06-22 2010-09-16 サイドース・エルエルシー Tween80を含まないドセタキセル可溶化製剤
US20090087460A1 (en) * 2007-10-02 2009-04-02 Hamamatsu Photonics K.K. Solid composition, microparticles, microparticle dispersion liquid, and manufacturing methods for these
AR063111A1 (es) 2007-10-03 2008-12-30 Eriochem Sa Una formulacion farmaceutica de taxano
KR101478779B1 (ko) * 2007-11-22 2015-01-05 에스케이케미칼주식회사 재수화시간이 향상된 택산 유도체 함유 동결건조 조성물 및이의 제조방법
KR101502533B1 (ko) * 2007-11-22 2015-03-13 에스케이케미칼주식회사 우수한 안정성을 갖는 택산 유도체 함유 주사제용동결건조 조성물 및 이의 제조방법
EP2106786A1 (de) * 2008-04-04 2009-10-07 Roewer, Norbert, Univ.-Prof. Dr. med. Pharmazeutische Zubereitung mit permethyliertem Cyclodextrin
US8912228B2 (en) 2009-10-19 2014-12-16 Scidose Llc Docetaxel formulations with lipoic acid
KR20120130740A (ko) * 2011-05-23 2012-12-03 에스케이케미칼주식회사 도세탁셀을 함유하는 액상 주사용 조성물
US11406595B2 (en) * 2012-05-21 2022-08-09 University Of Maryland, College Park Highly stable colloid from aqueous solutions of small organic molecules
JP6235603B2 (ja) 2012-11-15 2017-11-22 ザピオテック・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングSAPIOTEC GmbH 消炎性および/または免疫抑制性活性成分としてのデルフィニジン複合体
JP6234476B2 (ja) 2012-12-11 2017-11-22 ザピオテック・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングSAPIOTEC GmbH メラノーマ細胞に対抗するためのデルフィニジン
CN105823810A (zh) * 2016-01-04 2016-08-03 杭州电子科技大学 紫杉醇化疗效果检测装置及检测方法
KR101829705B1 (ko) * 2016-09-21 2018-02-19 씨제이헬스케어 주식회사 안정성이 향상된 주사용 조성물
KR102262743B1 (ko) 2017-07-07 2021-06-09 에이치케이이노엔 주식회사 주사용 조성물
CN113456586B (zh) 2018-07-25 2022-06-10 比卡生物科技(广州)有限公司 一种注射用多西他赛组合物及其制备方法
JP2024519586A (ja) * 2021-05-26 2024-05-17 デウン ファーマシューティカル カンパニー リミテッド 1-(5-(2,4-ジフルオロフェニル)-1-((3-フルオロフェニル)スルホニル)-4-メトキシ-1h-ピロール-3-イル)-n-メチルメタンアミンを含む新規な注射用製剤
CN115960834B (zh) * 2023-03-07 2023-06-09 浙江省肿瘤医院 一种pd-1/ptx联合pd-1耐药模型建立的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5602112A (en) * 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
JPH06157330A (ja) * 1992-11-27 1994-06-03 Ensuiko Sugar Refining Co Ltd タキソールのサイクロデキストリン包接物,その製造法と用途
JPH0753396A (ja) * 1993-08-19 1995-02-28 Ensuiko Sugar Refining Co Ltd タキソールのサイクロデキストリン包接物,その製造法および用途
HU213200B (en) * 1993-05-12 1997-03-28 Chinoin Gyogyszer Es Vegyeszet The cyclodextrin or cyclodextrin derivative cluster complexes of taxol, taxotere, or taxus, pharmaceutical preparations containing them and process for their production
DE4414138A1 (de) * 1994-04-22 1995-10-26 Consortium Elektrochem Ind Acylierte gamma-Cyclodextrine
HUT73844A (en) * 1994-11-11 1996-09-30 Chinoin Gyogyszer Es Vegyeszet New taxol complexes and pharmaceutical compositions containing them
CA2163837C (en) * 1994-12-13 1999-07-20 Robert K. Perrone Crystalline paclitaxel hydrates
EP1451168A4 (en) * 2001-11-30 2005-08-24 Bristol Myers Squibb Co PACLITAXELSOLVATE

Also Published As

Publication number Publication date
AU1253899A (en) 1999-05-31
KR20010031967A (ko) 2001-04-16
ATE387916T1 (de) 2008-03-15
WO1999024073B1 (en) 1999-07-08
IL135990A0 (en) 2001-05-20
EA002776B1 (ru) 2002-08-29
JP2001522816A (ja) 2001-11-20
PL199652B1 (pl) 2008-10-31
JP3656550B2 (ja) 2005-06-08
KR100607391B1 (ko) 2006-08-02
CA2309326A1 (en) 1999-05-20
US20070087999A1 (en) 2007-04-19
HUP9701945A3 (en) 2000-04-28
PL340505A1 (en) 2001-02-12
DE69839224T2 (de) 2009-04-16
AR015482A1 (es) 2001-05-02
CN1222321C (zh) 2005-10-12
DE69839224D1 (de) 2008-04-17
WO1999024073A1 (en) 1999-05-20
BR9814015A (pt) 2000-09-26
US7671042B2 (en) 2010-03-02
AU742036B2 (en) 2001-12-13
NO329382B1 (no) 2010-10-04
EA200000494A1 (ru) 2000-10-30
CA2309326C (en) 2010-12-21
CN1281373A (zh) 2001-01-24
EP1059942B1 (en) 2008-03-05
NO20002165D0 (no) 2000-04-27
HU9701945D0 (en) 1998-01-28
EP1059942A2 (en) 2000-12-20
ZA989779B (en) 1999-04-28
NZ504098A (en) 2003-06-30
HUP9701945A1 (hu) 1999-09-28

Similar Documents

Publication Publication Date Title
NO20002165D0 (no) Farmasøytiske blandinger inneholdende cyklodekstriner og taksoider
NO995925D0 (no) Farmasöytiske sammensetninger omfattende cyklodekstriner
CY2005007I2 (el) Φαρμακευτικες συνθεσεις που περιεχουν δαριφενακινη
DE69618587T2 (de) Chinazoline und pharmazeutische zusammensetzungen
DE69704612D1 (de) Dentalmasse und dental-produkt
ATE277615T1 (de) Therapeutische zusammensetzungen, enthaltend amlopidin und atorvastatin
IS4706A (is) Lyfjasamsetningar
DE69924999D1 (de) Lipasehemmer enthaltende pharmazeutische zusammensetzungen
ITRM960810A0 (it) Composizioni farmaceutiche contenenti ciclosporine o macrolidi
ID18352A (id) Komposisi-komposisi farmasi
MA26553A1 (fr) Alpha-aryl-n-alkylnitrones et compositions pharmaceutiques contenant ceux-la
DK0847391T3 (da) Aromatiske forbindelse og farmaceutiske præparater indeholdende disse
BR9509688A (pt) Composto e composição farmacêutica
IS4809A (is) Taxóíð, efnasmíði þeirra og lyfjasamsetning sem inniheldur þau
IS5184A (is) Lyfjasamsetningar
EE9900206A (et) N-sulfonüülindoliiniderivaate sisaldavad farmatseutilised kompositsioonid
DK1005342T3 (da) Farmaceutiske sammensætninger indeholdende tizoxanid og nitazoxanid
PT941100E (pt) Composicoes farmaceuticas
PT986537E (pt) Novos compostos heteroetinilenos e composicoes farmaceuticas e cosmeticas contendo-os
EE200000330A (et) Farmatseutilised kompositsioonid
DK1066261T3 (da) Pyridinderivat og farmaceutisk præparat indeholdende samme
NO975365D0 (no) Benzopyraner og farmasöytiske sammensetninger inneholdende dem
ZA982457B (en) Pharmaceutical compositions containing propanaminde derivatives and cyclodextrin
ITMI962628A0 (it) Composizione farmaceutica
NO994436L (no) Farmasöytiske sammensetninger

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application
MM1K Lapsed by not paying the annual fees